(Q39918490)

15 September 2017

title

Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. (English)

1 reference

15 September 2017

1 reference

G Escherich

1

1 reference

15 September 2017

M A Horstmann

2

1 reference

15 September 2017

M Zimmermann

3

1 reference

15 September 2017

G E Janka-Schaub

4

1 reference

15 September 2017

COALL study group

5

1 reference

15 September 2017

publication date

17 December 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

24

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

298-308

1 reference

[In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study C

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

A Cox regression model for the relative mortality and its application to diabetes mellitus survival data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

7 January 2021

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

7 January 2021

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

7 January 2021

Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

7 January 2021

Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.249

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.249

1 reference

15 September 2017

1 reference